Taysha Gene Therapies Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
TSHA$4.33+5.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
Condensed Consolidated Statements of Operations
| For the Three MonthsEnded March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $3,411 | $4,706 |
| Operating expenses: | ||
| Research and development | 20,657 | 12,514 |
| General and administrative | 7,084 | 8,751 |
| Total operating expenses | 27,741 | 21,265 |
| Loss from operations | (24,330) | (16,559) |
| Other income (expense): | ||
| Change in fair value of warrant liability | (337) | — |
| Change in fair value of term loan | (1,053) | — |
| Interest income | 1,693 | 319 |
| Interest expense | (29) | (1,374) |
| Other expense | (5) | (8) |
| Total other income (expense), net | 269 | (1,063) |
| Net loss | $(24,061) | $(17,622) |
| Net loss per common share, basic and diluted | $(0.10) | $(0.28) |
| Weighted average common shares outstanding, basic and diluted | 231,249,344 | 63,260,905 |
Condensed Consolidated Statements of Comprehensive Loss
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net loss | $(24,061) | $(17,622) |
| Other comprehensive loss: | ||
| Change in fair value of terms loan attributable to instrument specific credit risk | (251) | — |
| Comprehensive loss | $(24,312) | $(17,622) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.